Biohaven (BHVN) news
Recent news
Biohaven shares gain 5% on SK Biopharma epilepsy licensing deal worth up to $795 million
AInvest Wire · 5d agoBiohaven - Eligible for $150 mln in development and regulatory milestones plus global royalties
Biohaven Ltd. (NYSE: BHVN) is currently positioned to receive up to $150 million in development and regulatory milestone payments, contingent on the achievement of specific clinical and regulatory goals, as outlined in its agreement with Oberland Capital Management LLC. This funding is part of a…
AInvest Wire · 5d agoBiohaven - To receive $400 mln cash, including $350 mln at closing and $50 mln in 2027
AInvest Wire · 5d agoBiohaven and SK Biopharmaceuticals enter into strategic global licensing agreement for novel Kv7 ion channel platform and opakalim, lead candidate for epilepsy
Biohaven Pharmaceuticals Inc. and SK Biopharmaceuticals Co., Ltd. have announced a strategic global licensing agreement for Biohaven’s Kv7 ion channel platform and its lead candidate, opakalim, a potential treatment for epilepsy. Under the terms of the agreement, SK Biopharmaceuticals will obtain…
AInvest Wire · 5d agoSK Biopharm signs up to $795M license-in deal with Biohaven
AInvest Wire · 5d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.